Encephalitis, Tick-Borne: all 51 studies

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• FINtick - a Prospective Multicenter Study on Tick-borne Infections in FinlandRecruitingNCT07897825
• Dexamethasone in Tick-borne EncephalitisRecruitingNCT07584525Phase 3
• First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.Not yet recruitingNCT07377253Phase 1
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
• Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech RepublicRecruitingNCT07274046
• Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in FranceRecruitingNCT07191223
• Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne DiseasesNot yet recruitingNCT06859619Not applicable
• Primary TBE Vaccination for the ElderlyNot yet recruitingNCT04573205Phase 4
• Tick-borne Encephalitis and Borrelial Antibodies in SerumRecruitingNCT03956446Not applicable
• Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and OlderCompletedNCT04648241Phase 3Results posted
• Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT RecipientsCompletedNCT01991067Phase 2Results posted
• Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination SchedulesCompletedNCT01562444Phase 4Results posted
• Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)TerminatedNCT01031537Phase 2Results posted
• Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)CompletedNCT00894686Phase 4Results posted
• Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in ChildrenCompletedNCT00840801Phase 3Results posted
• Management of Tick-borne EncephalitisCompletedNCT06593249
• Tick-borne Encephalitis Virus Research in LimousinCompletedNCT05941546
• Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric CasesCompletedNCT05607394
• The NOrwegian Tick-borne Encephalitis StudyActive, not recruitingNCT05138055
• Application of a TBE-Vaccine in Obese PersonsStatus unknownNCT04017052Phase 4
• Tick-borne Encephalitis and Possible Borrelial SerologyCompletedNCT03958058
• Fever After Tick Bite StudyWithdrawnNCT03932448
• Tick-borne Encephalitis and Positive Borrelial AntibodiesStatus unknownNCT02463942Not applicable
• Aseptic Meningoencephalitis in SloveniaStatus unknownNCT02328469
• New Study - Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT02318069Phase 2/3
• Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVacCompletedNCT01710189Phase 4
• TBE Seropersistence up to 10 Years After First Booster in AdultsCompletedNCT01582698Phase 4
• Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT01361776Phase 2/3
• An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBECompletedNCT01106482Phase 4
• Postencephalitic Symptoms After Tick Borne EncephalitisStatus unknownNCT00941590
• Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus VaccineStatus unknownNCT00890422Phase 2
• Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis VaccinationCompletedNCT00804219Phase 4
• TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)CompletedNCT00503529Phase 4
• Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization ScheduleCompletedNCT00460486Phase 3
• Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five YearsCompletedNCT00452621Phase 4
• Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for AdultsCompletedNCT00311493Phase 4
• Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy ChildrenCompletedNCT00311441Phase 4
• Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in ChildrenCompletedNCT00163618
• Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)CompletedNCT00163540Phase 4
• TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)CompletedNCT00161967Phase 4
• Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 YearsCompletedNCT00161954Phase 4
• FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsCompletedNCT00161889Phase 2
• FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 YearsCompletedNCT00161876Phase 3
• Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 YearsCompletedNCT00161863Phase 3
• FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsCompletedNCT00161850Phase 2
• Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPURCompletedNCT00161824Phase 3
• Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.CompletedNCT00161798Phase 2
• Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 YearsCompletedNCT00161785Phase 4
• Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.CompletedNCT00161772Phase 2
• Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 YearsCompletedNCT00161746Phase 2/3
• Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy AdultsCompletedNCT00118924Phase 1

← Encephalitis, Tick-Borne overview